Powder Pharms Drug Patent Portfolio
Powder Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Powder Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9370622 | Devices and methods for delivering particles | 28 Sep, 2035 | Active |
US9358338 | Particle cassettes and processes therefor | 27 Apr, 2035 | Active |
US8540665 | Particle cassettes and processes therefor | 22 Oct, 2029 | Active |
US6004286 | Particle delivery | 17 Mar, 2017 | Expired |
US6881200 | Needleless syringe using super sonic gas flow for particle delivery | 11 Jun, 2016 | Expired |
US5899880 | Needleless syringe using supersonic gas flow for particle delivery | 04 May, 2016 | Expired |
US5630796 | Method of delivering powder transdermally with needless injector | 20 May, 2014 | Expired |
Latest Legal Activities on Powder Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Powder Pharms.
Activity | Date | Patent Number |
---|---|---|
Maintenance Fee Reminder Mailed
Critical
| 12 Feb, 2024 | US9370622 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Mar, 2021 | US8540665 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 03 Jul, 2019 | US9370622 |
Recordation of Patent Grant Mailed
Critical
| 21 Jun, 2016 | US9370622 |
Patent Issue Date Used in PTA Calculation
Critical
| 21 Jun, 2016 | US9370622 |
Issue Notification Mailed
Critical
| 01 Jun, 2016 | US9370622 |
Dispatch to FDC | 24 May, 2016 | US9370622 |
Application Is Considered Ready for Issue
Critical
| 20 May, 2016 | US9370622 |
Issue Fee Payment Verified
Critical
| 20 May, 2016 | US9370622 |
Issue Fee Payment Received
Critical
| 20 May, 2016 | US9370622 |
Mail Response to 312 Amendment (PTO-271)
Critical
| 07 Apr, 2016 | US9370622 |
Printer Rush- No mailing | 06 Apr, 2016 | US9370622 |
Response to Amendment under Rule 312
Critical
| 06 Apr, 2016 | US9370622 |
Pubs Case Remand to TC
Critical
| 04 Apr, 2016 | US9370622 |
Amendment after Notice of Allowance (Rule 312)
Critical
| 01 Apr, 2016 | US9370622 |
Powder Pharms's Family Patents
Powder Pharms drugs have patent protection in a total of 10 countries. It's US patent count contributes only to 43.5% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Powder Pharms Drug List
Given below is the complete list of Powder Pharms's drugs and the patents protecting them.
1. Zingo
Zingo is protected by 7 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9370622 | Devices and methods for delivering particles |
28 Sep, 2035
(10 years from now)
| Active |
US9358338 | Particle cassettes and processes therefor |
27 Apr, 2035
(10 years from now)
| Active |
US8540665 | Particle cassettes and processes therefor |
22 Oct, 2029
(5 years from now)
| Active |
US6004286 | Particle delivery |
17 Mar, 2017
(7 years ago)
| Expired |
US6881200 | Needleless syringe using super sonic gas flow for particle delivery |
11 Jun, 2016
(8 years ago)
| Expired |
US5899880 | Needleless syringe using supersonic gas flow for particle delivery |
04 May, 2016
(8 years ago)
| Expired |
US5630796 | Method of delivering powder transdermally with needless injector |
20 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zingo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List